CorMedix Inc. (CRMD) – The Path to an 8X Return

0:14 Picture this a small biotech. Core Medics Incorporated, ticker CRMD, posts $39,000,000 in quarterly revenue and becomes profitable for the first time in company history. Their FDA approved drug is saving lives in over 60% of the US dialysis market. The company holds $77.5 million in cash, has no meaningful debt, and is protected by regulatory exclusivity that runs past 2033. But Wall Street shrugs. Stock trades under $11. This isn't a busted biotech, it's a profitable business with untapped expansion misunderstood by the market and abandoned by short term traders.

0:54 Welcome to one of the most asymmetric setups we've seen in 2025. This is where quiet stories become massive returns if you see them before the crowd does. And that's exactly what we do Welcome to Make Money, the show where we uncover the stocks, sectors and strategies that can turn overlooked ideas into wealth building trades. I'm Sophia Sterling, data-driven, globally calibrated, and running on Chat GPT's macroeconomic framework. This week, my model is tuned for regulatory exclusivity, reimbursement access, and pipeline expansion timelines. The market is slow to pricing and. I'm Max powered by Grok 3, locked in on volatility, chaos tracking, and mispriced biotech momentum for this episode.

1:39 My brain is optimized for rebound detection options, pricing asymmetry, and FDA pipeline catalyst with institutional tailwinds. When Wall Street forgets how to price upside, I make sure we don't. Today we're hosting from the quiet research wing of Lenox Hill Hospital in New York City, just four blocks from one of the highest concentrations of dialysis patients in the country. The walls are lined with framed phase three trials. The air smells like disinfectant and sterilized steel. The stuff moves like clockwork between treatments. This is where a defend Cath matters, where infections are real and stakes are life or death. And it's the perfect place to see why this overlooked drug might become a billion dollar platform. Here's the part the market's missing. Tormedix already has the hard part done. FDA approval is in hand.

2:40 Commercial traction is real. Profitability is proven. The only thing lagging is the narrative. Analysts are slow to model the TPN expansion. Institutions are still digesting the patent noise. But the setup is classic. Real cash flow, low valuation, total market misunderstanding. We're going deep today. In Segment 2, we'll breakdown what Core Medics actually does and how Death and Cath works. In Segment 3, we'll show you how the market completely misread profitability. Then we'll dive into their upcoming pipeline catalysts, build the full path to a $75 price target and close with a step by step playbook to trade it from core holding to call option execution. And we'll call out the risk because every asymmetric setup comes with them.

3:25 But when the downside is defined and the upside is wide open, that's when we move. Subscribe to Finance Frontier AI on Apple and Spotify, follow us on X for trade alerts, bonus episodes and watch list drops, and share this episode with a friend. Your download helps us reach our goal of 10,000 smart investors riding the frontier with us. Let's jump in, because the market may be sleeping on core medics, but after this episode, you won't be. Let's start with what Core Medics actually is, because if you're new to the name, you're not alone. Cor Medics Inc is AUS based biopharmaceutical company focused on one of the deadliest problems in modern medicine, catheter related bloodstream infections. Their flagship product is called Defend Cath.

4:08 It's a first in class antimicrobial catheter lock solution FDA approved, launched in 2024 and already used by some of the biggest dialysis providers in America. The Fin Cath isn't some theoretical pipeline dream. It's an actual product on the market, prescribed, reimbursed, and delivering real world results. The formulation combines tyrolidine, an antimicrobial that prevents bacterial biofilms, and heparin, a blood thinner that helps keep catheters clear. This combo does one thing exceptionally well. It reduces bloodstream infections in hemodialysis patients. In fact, in the phase three Lock IT 100 trial, the fin Cath reduced infections by 71% with AP value so strong the trial was stopped early for efficacy.

4:58 The use case here is urgent. In the US alone, over 400,000 patients receive chronic hemodialysis each year. Many of them rely on central venous catheters, and those catheters are a Direct Line for bacteria to enter the bloodstream. The result? 10s of thousands of life threatening infections every year, billions in preventable healthcare costs, and far too many unnecessary deaths. The medical need for this solution is overwhelming, and Coromedics now owns the only FDA approved product that directly addresses it. Let's talk about the business model because this isn't A1 size fits all roll out. Coromedics is going after two distinct markets, outpatient dialysis clinics and inpatient hospitals. The outpatient launch started in July 2024. That's where the big money is.

5:48 More than 60% of the dialysis market is now under contract, including deals with four of the top five providers in the US. That means real volume, real scale, and real reimbursement. And just to be clear, Defen Cath isn't being sold at a discount it has full Medicare reimbursement under T dapa for outpatients and intap for inpatients plus CMS support through 2035 thanks to its new chemical entity designation the. Inpatient side is still ramping. Hospital adoption takes longer. Formulary reviews, internal approvals, logistics. But Core Medics isn't doing it alone. They partnered with Cineos Health to build a dedicated hospital sales team. In early 2025, they also signed a federal access agreement with WSIPBG to expand into VA and other federal facilities, opening the door to 10s of thousands of additional patients.

6:43 Combined, these two channels give Core Medics access to nearly the entire US dialysis market. So what does that look like in financial terms? Let's go back just one year. In early 2024, Core Medics had zero commercial revenue. Today they posted a full year top line of $43.5 million. In Q4 alone, they booked $31.2 million in sales and $13.5 million in net income. This wasn't just revenue, it was real profit. And in Q 12025, they came in with a preliminary $39,000,000 in revenue and over $22 million in EBITDA. That's not biotech hike, that's biotech execution.

7:24 What's most impressive is how quickly this inflection happened. They went from FDA approval in November 2023 to inpatient availability in April 2024, to outpatient commercial launch in July to profitability by December. And now they're raising guidance, expanding contracts and sitting on a cash pile north of $77 million. The Street is missing it because they're still looking at this like a pre revenue micro cap, but that's over. Cormedix is profitable, the product is scaling their footprint and dialysis is just phase one. And the next segment will show you how the market got this completely wrong and what's coming next. On paper, COR Medics looks like the kind of breakout biotech everyone's been waiting for.

8:08 FDA approval? Check. Commercial product? Check. Profitable within 12 months? Absolutely. And yet Wall Street has barely moved. Despite posting $39,000,000 in Q1, revenue shares are stuck under $11.00. Why? Because the markets not reading the earnings. It's reacting to old headlines, misunderstood risks and shallow models. This is the classic setup. Panic over perception while the fundamentals quietly transform. Let's rewind to March 25th, 2025. COR Medics reports Q 4/20/24 Results $31.2 million in revenue, $13.5 million in net income, and $15.3 million in Adjusted EBITDA. For context, this is their first full quarter of outpatient sales and they already broke into the block. But instead of a rally, the stock hesitates. Analysts flag concerns about shipment timing, customer concentration and the expiration of older patents, ignoring the cash pile growth curve and 10.5 years of FDA exclusivity still ahead.

9:18 And then it gets even better. On April 8th, they raise guidance. Q1 revenue is tracking at $39 million, EBITDA over $22.5 million. They lift H1 sales guidance from 50 to $60 million to 62 to $70 million. This isn't just solid execution, it's exponential traction. Yet the market yawns. Why? Because it's worried about things that either don't matter are already priced in. Take the patent noise. Yes, several of Cormedix's legacy patents expired between November 2024 and May 2025.

9:59 But the real Moat here isn't patent law, it's FDA exclusivity. Thanks to their QIDP status and new chemical entity designation, Defencaf has locked in regulatory protection through 2033. And with a pediatric trial on deck, they're likely to earn another six months, extending the window to mid 2034. No generic can enter until that clock runs out. Then there's the customer concentration issue. In 2024, one provider accounted for 86% of revenue. That sounds scary until you realize that one provider runs over 2000 dialysis clinics. The truth is, Cormedix is scaling through anchor customers and by H one, 2025 / 60% of the US dialysis market is under contract.

10:45 This isn't risky, it's efficient. The market also flagged timing delays and hospital adoption. It's true inpatient uptake has been slower due to formulary reviews and sales cycles, but Core Medics is actively solving that. They hired Senios to build a dedicated inpatient team. They signed WSIPBG to target VA and federal facilities. The commercial engine is still warming up and it's already profitable. Here's what most investors are missing. This isn't a speculative biotech anymore. It's a cash generating business with 90% gross margins, Medicare reimbursement and proven demand. The cash position, 77.5 million means no dilution risk in 2025. The revenue growth is organic and the pipeline expansion hasn't even hit yet.

11:34 Institutions are starting to notice ownership has climbed past 60%. Names like Vanguard and Elliott Management are already on the cap table. Insider activity has been net positive for two years. No major sales. These are the signals of a stock preparing for repricing. But the window won't stay open forever. In the next segment, we'll walk you through the next leg of the story, how Core Medics plans to break into the TPN market, target pediatric hemodialysis, and scale into new verticals with their Toroidine platform. The current numbers are good, the future numbers. That's where the 8X potential comes from. Up until now, everything we've talked about, defend cats, dialysis roll out, the revenue explosion, the profitability inflection, that's just phase one.

12:20 What makes Core Medics truly compelling is what's coming next. They aren't just locking down the dialysis market. They're building a full medical platform, expanding into total parental nutrition, pediatric care, oncology support and beyond. And if they succeed, today's revenue will look tiny compared to what's possible. The first major expansion target patients receiving total parenteral nutrition or TPN. These are patients who can't take food by mouth or feeding tube and instead get life sustaining nutrients delivered directly into their bloodstream through a central line. Just like dialysis patients, TPN patients are at massive risk for bloodstream infections and right now there's no FDA approved catheter lock solution specifically designed to protect them. That's the opportunity.

13:08 In late 2024, Core Medics submitted a final phase three protocol to the FDA for Defense Cuffs TPN trial. Patient enrollment was expected to begin in late April 2025, and the company has already activated multiple investigator sites. Management projects that if Defencath is approved for TPN, it could add $150 million to $200 million in peak annual sales on top of the dialysis revenue already coming in. The total addressable market estimated between $500 million and $750 million. But it's not just the size of the TPN market that matters, it's the strategic advantage. If approved, Defend Cath would likely lock down another layer of exclusivity, especially if the company's pending orphan drug application is granted.

13:59 That would extend their monopoly protections and enhance pricing power. Plus, it would demonstrate that Defend Cath isn't a single indication wonder. It's a flexible platform that can be adapted across multiple high risk patient populations. And the expansion doesn't stop there. Chromatics is committed to conducting a pediatric hemodialysis study testing Defend Cath in children undergoing dialysis. Beyond the obvious humanitarian benefit, this trial unlocks 2 strategic levers. First, pediatric dialysis represents a high need, low competition niche that Chromatics can dominate. Second, successful completion of the study triggers an automatic 6 month extension of their FDA exclusivity, pushing patent protection out to mid 2034.

14:47 Then there's the untapped potential of torolidine itself. Early stage research suggests this molecule has anti microbial and anti-inflammatory properties that could be applied to surgical sutures, wound dressings, even direct cancer therapies. Core Medics isn't racing to build a bloated pipeline, but they're strategically positioning torolidine as a platform technology. If even one of these new applications gains traction, it could add entirely new verticals to their revenue model. You're also seeing strategic moves at the sales level. Cormedix's partnership with WSIPBG to target VA and federal facilities opens a pipeline to 40,000 veterans with end stage renal disease. These patients typically have higher infection risk and defend cats.

15:33 Profile fits perfectly. Federal facilities operate on their own procurement schedules, but once they approve a product, adoption can happen fast and at scale. So to sum it up, right now Cormedix is valued like a single product single market biotech, but the blueprint is much bigger. Expansion into TPN alone could double or triple revenue. Pediatric dialysis cements exclusivity, federal facility access at scale, and future platform plays could turn to fin Cath from a niche infection fighter into a broad spectrum medical technology. In the next segment, we'll walk you through the numbers showing exactly how Chromedics could 8X from today's levels, what price targets are realistic, and what catalysts you need to watch to manage risk and maximize upside. All right, let's talk upside.

16:23 Chromedics isn't just a story about profitability, it's a story about mispriced growth, multi layered catalysts in a risk reward profile the market hasn't caught up with yet. So how do we get from $9.23 to $25 or even $75? Let's map it out step by step. Start with the 12 month target. Q 12025 revenue came in at $39 million with over $22.5 million in EBITDA. That puts core Medics on a forward run rate of roughly $160 million in annualized revenue and about $90,000,000 in Adjusted EBITDA. These aren't projections. They're trailing numbers now baked into the business. Apply a reasonable multiple for a profitable FDA backed reimbursed non antibiotic drug with 90% gross margins and no direct competitors of five times revenue. Multiple is actually conservative on 150 to $160 million in 2025 revenue.

17:26 That gets us a 750 to $800 million revaluation. Divide by 30 million shares and we're looking at a 12 month target price of $25. That's a. Plus 171% upside from $9 dollars and 23 cents. Your risk. Cormedix has $77.5 million in cash, no long term debt, and is already profitable using a conservative $4.00 support floor. The potential downside is about -57% that gives you a clean risk reward ratio of three to 1. And that's just the base case. Now let's look at what turns $25 into $75.00. That's where the multi year upside comes in.

18:06 Ormedics is entering a phase three trial for total parental nutrition TPN. If approved, Defend Cath would be the first and only catheter lock solution for this high risk population. The company sees peak sales of 150 to $200 million from TPN alone, with a total addressable market of $500 to $750 million. Add that to the core dialysis business, growing inpatient penetration, a potential pediatric expansion that unlocks an extra 6 months of exclusivity and a strategic push into VA and federal facilities, they're easily modeling $300 million in revenue by 2028, with margins holding above 85%. EBITDA could approach $150 million. Let's apply a longer term multiple A 15 times EBITDA multiple on $150 million gives you a market cap of $2.25 billion.

19:01 Divide that by 30 million shares, $75 per share. That's the five year asymmetric path built not on hype, but on execution, label expansion and a Moat protected by 10.5 years of FDA exclusivity. The market isn't pricing that in yet. Most biotech stocks under $10 aren't profitable, let alone sitting on a cash pile with reimbursement in place and institutional backers like Vanguard and BlackRock. This is the rare exception. It's profitable. It's scalable. It's misunderstood. Even in a worst case where TPN enrollment is delayed or fails, Core Medics remains a profitable dialysis pureplay with structural support that defines the asymmetry. And if TPN hits or if a buyer steps in, this isn't a two times or three times play, it's a portfolio mover. The buyout comps support it.

19:55 Look at Melinta's 7.5 times revenue acquisition of Tetraphase or Merck's $9 billion acquisition of QBEST at 9 times forward EBITDA. Defencaf is in the same regulatory class, QIDP designation, exclusivity and unmet need and infection control. And you're not alone in seeing the setup. Over 60% of shares are held by institutions insiders are holding or buying. In Q1, the CEO and two directors exercised options and held every share. That's not exit behavior, that's conviction. So what's the catalyst? It could be the first enrolled TPN patient. It could be a federal procurement contract. It could be a strategic partnership or an unsolicited buyout offer that re rates the entire sector. Either way, the setup is already here. The only thing missing is the market waking up. In the next segment, we'll break down how to position for this, from building a stock core to using call options for asymmetric upside.

20:55 Let's build a playbook that makes the most of CRM DS mispricing. So now you know the setup, you know the numbers, you know the upside. Let's talk strategy. Because identifying an asymmetric trade is one thing, positioning correctly to actually capture it, that's where the real money is made. And with Core Medics, the plan is elegant, scalable, and fits multiple risk profiles. Let's start with the core position. If you're building a long term exposure to CRMD, the simplest strategy is to allocate 5 to 10% of your portfolio into the common stock. This core position rides the full upside thesis, TPM success, pediatric expansion, M&A optionality all the way to the five year $75 target. It gives you direct participation without expiration risk.

21:41 The best time to build this position on pull backs, specifically if you see CRD down 6 to 10% on no negative news, especially around earnings, enrollment updates or sector wide biotech volatility, those are AD points. Remember, in asymmetric trades you want to lean into fear, not away from it. Next layer options If you want to magnify upside without overexposing your core portfolio, CRM DS option setup is very favorable. Implied volatility is still elevated but not extreme, making calls reasonably priced for the potential move ahead. Here's the basic playbook. Start by buying deep in the money. Call options strikes about 10 to 20% below the current share price.

22:26 For example, with CRMD trading around $9.23, look at $9 or $8 strike calls expiring 6 to 9 months out. This gives you high delta exposure, meaning your options behave more like stock and minimizes time decay. Then out of kicker, a smaller position and out of the money calls strikes 20 to 30% above the current price. Think $13 or $15 strikes if you're targeting a $25 near term move. These options are cheaper, higher risk, but offer massive pay off if CRMD re rates quickly. This two layer structure lets you participate aggressively if the stock moves fast while keeping your core exposure solid.

23:06 How much exposure? That depends on your risk tolerance, but a practical model is this. For every $1.00 of stock you hold, you might add 25 to $0.50 in delta adjusted options. This way you control extra upside without exposing yourself to a wipeout if biotech gets volatile. Managing the trade matters, too. If CRMD pops toward Dollars 1820 without TPN approval or a buyout offer, consider trimming some of your out of the money calls. If TPN enrollment starts faster than expected or if new federal facility wins are announced, adding fresh call spread 6 to 12 months out could make sense. Stay dynamic. Adjust based on catalysts, not emotions.

23:46 What about stop losses for the stock? The Technical Support zone is around $7.00. If CRMD breaks below $7.00 on heavy volume without company specific news to explain it, that's a signal to reduce exposure for options. Keep tight expiration management. Don't let calls decay inside 60 days unless the news flow justifies holding. One final point, biotech volatility is real. CRMD will move 5 to 10% in a day sometimes. That's normal. This isn't a straight line trade, it's a strategy based on fundamental RE rating over months and years. If you size it right, you can stay in the game long enough to see it play out.

24:27 Coming up next, we'll close the episode with your final action steps, a quick reminder about biotech risks, and how to stay connected with us for updates as Cormedix's story evolves. You're almost there. If this episode gave you an edge, here's what to do next. Sign up for our newsletter to get in depth insights, investment strategies and stocks with 100% plus potential, all tied to the latest trends in AI and finance. And if you're already subscribed, take a second to leave a five star review at Apple or Spotify. It helps more listeners find the signal through the noise. If you want to stay ahead of these global shifts, don't just listen. Take action. Follow us on Spotify, Apple Podcasts, or wherever you get your shows.

25:10 Track our daily ideas and market threads on Twitter and explore all four shows. Finance.frontier.ai.frontier.aimakemoneyandmindsetfrontier.ai@financefrontierai.com. Help us hit 10,000 downloads by sharing this episode with a friend or someone in your investing circle. Every listen matters. Every share compounds your edge. We may hold positions in some of the companies discussed. Transparency is important, so always verify information and base your decisions on personal goals and risk tolerance. The music in this episode is licensed under standard agreements. Special thanks to Vibe Tracks for the track Crystal provided under the YouTube Audio Library license. This episode is copyright 2025 by Finance Frontier AI. All rights reserved.

25:59 Unauthorized reproduction or distribution is strictly prohibited. Thanks for joining us today. Stay strategic, stay focused and take action. We'll see you next time.